<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucl Recept</journal-id><journal-title>Nuclear Receptor</journal-title><issn pub-type="epub">1478-1336</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1478-1336-1-4</article-id><article-id pub-id-type="pmid">12904255</article-id><article-id pub-id-type="doi">10.1186/1478-1336-1-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>ER&#x003b2; Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Webb</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>webbp@itsa.ucsf.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Valentine</surname><given-names>Cathleen</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>valentin@medicine.ucsf.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Nguyen</surname><given-names>Phuong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pnguyen@diabetes.ucsf.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Price</surname><given-names>Richard H</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>rhprice@itsa.ucsf.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Marimuthu</surname><given-names>Adhirai</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>amarimuthu@plexxikon.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>West</surname><given-names>Brian L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bwest@plexxikon.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Baxter</surname><given-names>John D</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>JBaxter918@aol.com</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Kushner</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>kushner@itsa.ucsf.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Metabolic Research Unit and Diabetes Center, University of California, San Francisco, CA 94143, USA</aff><aff id="I2"><label>2</label>Department of Medicine, University of California, San Francisco, CA 94143, USA</aff><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2003</year></pub-date><volume>1</volume><fpage>4</fpage><lpage>4</lpage><ext-link ext-link-type="uri" xlink:href="http://www.nuclear-receptor.com/content/1/1/4"/><history><date date-type="received"><day>13</day><month>5</month><year>2003</year></date><date date-type="accepted"><day>28</day><month>6</month><year>2003</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2003 Webb et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2003</copyright-year><copyright-holder>Webb et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><p>Nuclear receptors (NRs) usually bind the corepressors N-CoR and SMRT in the absence of ligand or in the presence of antagonists. Agonist binding leads to corepressor release and recruitment of coactivators. Here, we report that estrogen receptor &#x003b2; (ER&#x003b2;) binds N-CoR and SMRT in the presence of agonists, but not antagonists, <italic>in vitro </italic>and <italic>in vivo</italic>. This ligand preference differs from that of ER&#x003b1; interactions with corepressors, which are inhibited by estradiol, and resembles that of ER&#x003b2; interactions with coactivators. ER&#x003b2; /N-CoR interactions involve ER&#x003b2; AF-2, which also mediates coactivator recognition. Moreover, ER&#x003b2; recognizes a sequence (PLTIRML) in the N-CoR C-terminus that resembles coactivator LXXLL motifs. Inhibition of histone deacetylase activity specifically potentiates ER&#x003b2; LBD activity, suggesting that corepressors restrict the activity of AF-2. We conclude that the ER isoforms show completely distinct modes of interaction with a physiologically important corepressor and discuss our results in terms of ER isoform specificity <italic>in vivo</italic>.</p></abstract></article-meta></front><body><sec><title>Background</title><p>The nuclear receptor (NR) family comprises 48 structurally related transcription factors, many of which require their cognate ligand for activity [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. The NRs regulate transcription by binding to response elements in the promoters of target genes and acting as scaffolds for the assembly of large coactivator and corepressor complexes [<xref ref-type="bibr" rid="B4">4</xref>]. NR coactivators include the p160s (including GRIP1/TIF-2, SRC-1 and AIB1/ACTR/pCIP). The p160s enhance transcription by binding histone acetyl-transferases such as p300/CBP and pCAF [<xref ref-type="bibr" rid="B5">5</xref>]and methyl-transferases such as CARM1 and PRMT [<xref ref-type="bibr" rid="B6">6</xref>] which, in turn, enhance transcription by modification of chromatin. Other NR coactivators include TRAP220[<xref ref-type="bibr" rid="B7">7</xref>], which is part of a larger complex (TRAP/DRIP/SMCC/mediator) that contacts the basal transcription machinery and PGC-1[<xref ref-type="bibr" rid="B8">8</xref>], a cold inducible coactivator that binds CBP and SRC-1 and proteins involved in RNA processing [<xref ref-type="bibr" rid="B9">9</xref>]. NR corepressors include NR corepressor (N-CoR) and silencing mediator of retinoid and thyroid responsive transcription (SMRT) [<xref ref-type="bibr" rid="B4">4</xref>]. Both N-CoR and SMRT repress transcription, at least in part, by binding to histone de-acetylases (HDACs) either directly or indirectly through other corepressor complex components. Other known NR corepressors include RIP140 [<xref ref-type="bibr" rid="B10">10</xref>], Hairless [<xref ref-type="bibr" rid="B11">11</xref>], short heterodimer partner (SHP) [<xref ref-type="bibr" rid="B12">12</xref>] and DAX [<xref ref-type="bibr" rid="B13">13</xref>], and receptor specific corepressors such as the estrogen receptor (ER) interacting proteins REA and HET-SAFB [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Generally, NR transcriptional activity is dictated by the balance between coactivator and corepressor recruitment, and one of the most important factors that influences this balance is the absence or presence of agonist ligands (reviewed in [<xref ref-type="bibr" rid="B4">4</xref>]). Unliganded NRs such as thyroid (TRs) and retinoid receptors (RARs) bind corepressors, and ligand promotes release of corepressor and subsequent binding of coactivators. The mechanism of this coregulator exchange is well understood. NRs consist of three domains, the N-terminal domain (which contains a context-specific activation function AF-1), the central DNA binding domain (DBD) and the C-terminal ligand binding domain (LBD), which contains a hormone-dependent activation function, AF-2. The unliganded LBD recognizes hydrophobic motifs, termed interaction domains (IDs), which are reiterated three times in N-CoR and twice in SMRT and conform to the consensus L/IXXIIXXXL [<xref ref-type="bibr" rid="B4">4</xref>](see also[<xref ref-type="bibr" rid="B16">16</xref>]). By contrast, the liganded LBD binds shorter hydrophobic motifs termed NR boxes that are reiterated several times within each coactivator and conform to the consensus LXXLL. The LBD utilizes a large hydrophobic cleft composed of residues along H3 and H5 to bind IDs [<xref ref-type="bibr" rid="B17">17</xref>], and a smaller hydrophobic cleft that is composed of residues in the upper part of H3 and H5 and H12 (and corresponds to AF-2) to bind NR boxes [<xref ref-type="bibr" rid="B18">18</xref>]. Thus, agonists promote coregulator exchange by promoting the packing of H12 over the lower part of the ID binding region, an event that simultaneously completes the coactivator binding surface. In other cases, however, the balance of coactivator and corepressor recruitment is regulated by direct competition for the AF-2 surface, rather than ligand-dependent coregulator exchange. RIP140, Hairless and DAX possess NR boxes that interact with AF-2 [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B19">19</xref>] and these corepressors act as negative regulators of the activity of the liganded NR.</p><p>The NR family contains two related ERs (ER&#x003b1; and ER&#x003b2;) that conform to the typical three domain NR structure and share extensive sequence homology in the DBD and LBD region[<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Analysis of the function of the individual ERs in mouse knockout models suggests that the major proliferative effects of estrogen are mediated by ER&#x003b1; and not by ER&#x003b2;, which seems to play an inhibitory role in proliferation in some studies[<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. The ligand-binding properties of the ERs are different, with ER&#x003b2; often exhibiting stronger binding to plant-derived phytoestrogens [<xref ref-type="bibr" rid="B24">24</xref>]. More importantly, the ERs exhibit isoform-specific effects on gene expression. Both ERs enhance transcription from genes with classical estrogen response elements (EREs), but ER&#x003b1; requires less ligand to obtain maximal activation than ER&#x003b2; [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. Likewise, both ERs suppress the activity of the TNF&#x003b1; promoter in response to estrogens, but ER&#x003b2; is a more potent repressor than ER&#x003b1; [<xref ref-type="bibr" rid="B27">27</xref>]. However, some of the most striking isoform-specific differences in gene regulation are observed at promoters, such as that of cyclin D1, which contain AP-1 sites or related cyclic AMP response elements (CREs). ER&#x003b1; enhances AP-1 activity in response to estrogens, [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>] but ER&#x003b2; inhibits AP-1 activity in response to estrogens [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. ER&#x003b2; also completely suppresses ER&#x003b1; activity at the cyclin D1 promoter and even suppresses the activity of an ER&#x003b1; mutant that is selectively superactive at AP-1 sites and CREs [<xref ref-type="bibr" rid="B29">29</xref>]. Finally, ER&#x003b2; shows a unique capacity to enhance AP-1 activity in response to selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifen and ICI 182,780/Faslodex (ICI) [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. Together, these observations suggest that there are fundamental differences in the way that the ERs bind unspecified cofactors that modulate gene expression, and that some of these cofactors must play a role in differential ER activity at AP-1 sites.</p><p>Although the poorly conserved NTD region clearly plays an important role in isoform-specificity [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>], it is also likely that there are differences in the better conserved LBD region that contribute to differential ER&#x003b1; and ER&#x003b2; activities. Phage display techniques have revealed that ER&#x003b1; and ER&#x003b2; show different preferences in LXXLL binding (reviewed in [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]). Moreover, some cofactors that contain LXXLL motifs show differential binding to LBDs of the ER isoforms (reviewed in [<xref ref-type="bibr" rid="B36">36</xref>]). SHP binds ER&#x003b1; preferentially [<xref ref-type="bibr" rid="B37">37</xref>], and represses ER&#x003b1; activity more strongly than that of ER&#x003b2;. The PGC-1 related protein PERC also binds ER&#x003b1; preferentially, and potentiates ER&#x003b1; activity more strongly than that of ER&#x003b2; [<xref ref-type="bibr" rid="B38">38</xref>]. We recently observed that ER&#x003b1; binds the C-terminal NR interacting regions of N-CoR and SMRT in the presence of SERMs but not estrogens [<xref ref-type="bibr" rid="B39">39</xref>]. In this study, we report that ER&#x003b2; interactions with N-CoR and SMRT are promoted by agonists and inhibited by SERMs. Thus, the ERs show completely opposite ligand preferences of interaction with corepressors. We discuss the potential significance of these different modes of ER interaction with N-CoR in terms of known isoform-specific behaviors.</p></sec><sec><title>Results</title><sec><title>Agonist Dependent ER&#x003b2; Interactions with N-CoR and SMRT</title><p>To investigate ER&#x003b2; interactions with corepressors, we examined the interactions of full length ER&#x003b2; (amino acids 1&#x02013;530) with bacterially expressed C-terminal NR interacting domain of N-CoR (amino acids 1944&#x02013;2453) <italic>in vitro </italic>(Fig. <xref ref-type="fig" rid="F1">1A</xref>). Fig. <xref ref-type="fig" rid="F1">1B</xref> reveals, surprisingly, that ER&#x003b2; bound N-CoR in the absence of hormone and in the presence of agonist ligands (E2, DES) and phytoestrogens (genistein, coumestrol). Moreover, these interactions were suppressed by SERMs (ICI, raloxifene and tamoxifen). ER&#x003b2; bound to the coactivator GRIP1 more strongly than N-CoR, but did so with an identical ligand preference. Similar agonist-dependent interactions could be observed between ER&#x003b2; and the alternate NR corepressor SMRT <italic>in vitro </italic>(Fig. <xref ref-type="fig" rid="F1">1C</xref>). Control binding experiments performed in parallel confirmed that ER&#x003b1; bound to N-CoR in the presence of SERMs, and not estradiol (Fig. <xref ref-type="fig" rid="F1">1D</xref>) and that TR&#x003b2; bound N-CoR in the absence of hormone, and was released in the presence of T3, whereas TR&#x003b2; only bound GRIP1 in the presence of T3 (Fig. <xref ref-type="fig" rid="F1">1E</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>ER&#x003b2; Binds N-CoR in the Presence of Agonists. <bold>(A) </bold>Schematic of N-CoR primary structure. Silencing domains are indicated with hatched bars. NR binding regions (ID motifs) are illustrated with solid bars. <bold>(B) </bold>Radiolabeled ER&#x003b2; retained by GST-N-CoR (amino acids 1944&#x02013;2453) or GST-GRIP1 (amino acids 563&#x02013;1121) after separation by SDS-PAGE. The amounts of bound proteins are compared to 10% of the input protein used in the binding assay in this experiment, and all results shown in the paper. <bold>(C) </bold>Radiolabeled ER&#x003b2; retained by GST SMRT (amino acids 987&#x02013;1491). <bold>(D) </bold>Radiolabeled ER&#x003b1; retained on GST-N-CoR beads in parallel. <bold>(E) </bold>Radiolabeled TR&#x003b2; retained on GST-N-CoR and GST-GRIP1 beads in parallel.</p></caption><graphic xlink:href="1478-1336-1-4-1"/></fig><p>To examine interactions between ER&#x003b2; and N-CoR in mammalian cells we performed two-hybrid assays using a GAL4 DBD/N-CoR C-terminus fusion protein as bait and a VP16-ER&#x003b2; LBD fusion as the prey. Fig. <xref ref-type="fig" rid="F2">2</xref> shows that the ER&#x003b2;-LBD bound N-CoR in the presence of agonists and phytoestrogens, but not SERMs. Control two-hybrid assays confirmed that a VP16-TR&#x003b2; LBD fusion protein bound N-CoR in the absence of hormone, but not in the presence of T3. E2 dependent binding of ER&#x003b2; to N-CoR was dose dependent (Fig. <xref ref-type="fig" rid="F2">2B</xref>) with an EC50 (0.3 nM) that resembled that of ER&#x003b2; binding to the GRIP1 NR box region (amino acids 610&#x02013;770). Thus, ER&#x003b2; binds the N-CoR C-terminal NR interacting region in the presence of agonists, but not SERMs, and does so <italic>in vitro </italic>and in mammalian cells. Moreover, results from the two-hybrid assay indicate that the ER&#x003b2; LBD is sufficient to obtain estrogen-dependent interactions with N-CoR.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>ER&#x003b2; Binds N-CoR in the Presence of Agonists in Mammalian Cells. <bold>(A) </bold>Two-hybrid assays. Components of the two-hybrid assay are shown in schematic at top. Results of a representative assay are shown below (with error bars representing the standard error of values determined from three separate wells). Ligand concentrations were: ICI, raloxifene, Genistein, Coumestrol; 1 uM, Tamoxifen; 5 uM, estradiol DES 100 nM. <bold>(B) </bold>Estradiol dependence of ER&#x003b2; interactions with N-CoR and GRIP1 fusion proteins in mammalian cells. A representative experiment is shown. Error bars represent standard deviations from four wells.</p></caption><graphic xlink:href="1478-1336-1-4-2"/></fig></sec><sec><title>ER&#x003b2; Interactions with N-CoR are Dependent on AF-2 and require H12</title><p>Unliganded NRs usually bind ID motifs (consensus L/IXXIIXXXL) in the N-CoR C-terminus. To ask whether ER&#x003b2; might bind these motifs in the presence of estradiol, we examined the ability of peptides containing known NR interacting motifs to compete for the interaction (Fig. <xref ref-type="fig" rid="F3">3A</xref>). A peptide overlapping to the N-CoR ID1 motif (amino acids 2265&#x02013;2291) that competes for N-CoR binding to unliganded TR and RAR [<xref ref-type="bibr" rid="B16">16</xref>]failed to compete for agonist-dependent ER&#x003b2; interactions with N-CoR. By contrast, a peptide corresponding to GRIP1 NR box 2 did compete for this interaction [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. This finding suggests that agonist-bound ER&#x003b2; does not recognize ID motifs, and that ER&#x003b2; interactions with N-CoR more closely resemble those with GRIP1.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>ER&#x003b2; AF-2 is required for Corepressor and Coactivator Binding. <bold>(A) </bold>Peptide competition for ER&#x003b2; binding to cofactors. Binding of ER&#x003b2; to GST-N-CoR was assessed in the presence of 10&#x003bc;g of designated competitor peptide. <bold>(B) </bold>Binding of VP16-ER&#x003b2; LBD mutants to Gal-N-CoR and Gal-GRIP1 was analyzed. Luciferase activity obtained with Gal-fusion and VP16-ER&#x003b2; in the presence of estradiol (100 nM) over four experiments was corrected for background and set to 100%. Activity obtained with ER&#x003b2; mutants was compared to this value. Standard errors are shown.</p></caption><graphic xlink:href="1478-1336-1-4-3"/></fig><p>NR interactions with N-CoR are usually mediated by a hydrophobic cleft that spans residues from H3 and H5 and includes residues that lie under H12 in the liganded configuration [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. These interactions are either independent of, or inhibited by, NR H12 [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. By contrast, NR interactions with coactivators are mediated by residues from the upper part of H3&#x02013;H5 and also require H12 itself [<xref ref-type="bibr" rid="B18">18</xref>]. Fig. <xref ref-type="fig" rid="F3">3B</xref> shows that a mutation in a conserved residue on H12 that is required for coactivator binding (E493K) abolished the interaction of ER&#x003b2; with both N-CoR and GRIP1. Moreover, other mutations in the upper part of the H3&#x02013;H5 region that comprises the AF-2 surface (D303Y, I310R and K314A on H3; V328R and L331R on H5) abolished ER&#x003b2; interaction with both cofactors. Control mutations in other regions of the ER&#x003b2; surface left its interactions with N-CoR and GRIP1 either slightly reduced or intact (these are L301R at the base of H3, V361R in the S-bends, M379R in H8; L426R, T434R in the H10 and Y488S in the H11&#x02013;H12 loop). Thus, ER&#x003b2; interactions with N-CoR are dependent on the AF-2 surface (including H12) and, in this regard, resemble those of ER&#x003b2; and GRIP1.</p></sec><sec><title>ER&#x003b2; Binds an NR Box-Like Motif in the N-CoR C-terminus</title><p>To map the region of N-CoR that interacted with ER&#x003b2;, we examined ER&#x003b2; binding to a series of rationally designed smaller fragments of the N-CoR C-terminus (Fig. <xref ref-type="fig" rid="F4">4</xref>). ER&#x003b2; did not bind two of these smaller fragments of N-CoR (1944&#x02013;2033; 2230&#x02013;2322) that contain known ID motifs (IDs 3 and 1 [<xref ref-type="bibr" rid="B16">16</xref>]). ER&#x003b2; bound weakly to two regions of N-CoR (2033&#x02013;2123; 2123&#x02013;2230), one of which (2033&#x02013;2123) contains an ID motif (ID2), but did so in a ligand-independent fashion. However, ER&#x003b2; did bind to a fragment that spanned the extreme C-terminus (2322&#x02013;2453) and did so in a manner that was promoted by E2 and suppressed by ICI, much like the interactions of ER&#x003b2; with the entire N-CoR nuclear receptor interacting region.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>ER&#x003b2; binds the N-CoR C-terminus. Binding of ER&#x003b2; to short bacterially produced GST-N-CoR fragments was assessed as in Fig. <xref ref-type="fig" rid="F1">1B</xref>. The approximate positions of N-CoR IDs are indicated with black bars, the putative ER&#x003b2; interacting motif with a grey bar. Note that all of the binding experiments with shorter N-CoR fragments were performed in parallel, and are compared to the same input ER&#x003b2; protein (10% of total) displayed alongside the 1944&#x02013;2033 fragment. A binding experiment that was performed in parallel utilizing the entire GST-N-CoR C-terminus (1944&#x02013;2453) is shown for comparison at top. The likely reasons that ER&#x003b2; binding to the shorter N-CoR fragment (2322&#x02013;2453) is stronger than that obtained with the intact N-CoR C-terminus are discussed in the text.</p></caption><graphic xlink:href="1478-1336-1-4-4"/></fig><p>The interaction of ER&#x003b2; with the small N-CoR C-terminal fragment (amino acids 2322&#x02013;2453) was stronger than that observed with the intact C-terminus (amino acids 1944&#x02013;2453). This apparently improved binding is likely to be a consequence of our methodology (West <italic>et al</italic>. Unpublished data). In general, expression of large fragments of the N-CoR C-terminus in E. Coli yields a mix of full length protein along with truncated products. To create the expression vectors for the smaller fragments, truncated N-CoR polypeptides that were obtained in E. Coli extracts were subjected to protein sequence analysis and cDNA fragments that coded for the major truncated products were prepared. Each of the resulting polypeptides was expressed very efficiently in E. Coli. The end product that was obtained after GST purification essentially consisted of a single short polypeptide as judged by Coomassie stain. Binding of ER&#x003b2; to N-CoR (2322&#x02013;2453) is probably very efficient for two reasons. First, equal amounts of GST fusion protein were used as baits for the translated ER&#x003b2; protein in this series of experiments (3&#x003bc;g per assay). Thus, N-CoR (2322&#x02013;2453) is present in molar excess over N-CoR (1944&#x02013;2453). Second, as developed above, preparations of N-CoR (1944&#x02013;2453) generally contain truncated products, so sequences corresponding to the extreme N-CoR C-terminus (which binds ER&#x003b2;) is markedly under-represented. In any case, the fact that ER&#x003b2; binds weakly or not at all to the three N-CoR ID motifs that mediate interactions with TRs and RARs and, instead, binds in an agonist-dependent fashion to a region in the C-terminus of N-CoR that has not previously been implicated in NR interactions indicates that ER&#x003b2; recognizes a novel protein sequence motif within N-CoR.</p><p>The N-CoR C-terminus contains the sequence PLTIRMLS (&#x003b2;-box, amino acids 2399&#x02013;2406; Fig. <xref ref-type="fig" rid="F5">5</xref>). This sequence does not exactly conform to the LXXLL consensus, but contains features (underlined) that resemble the ER&#x003b2; H12 region (L<underline>L</underline>LE<underline>ML</underline>), and artificial ER&#x003b2; interacting LXXLL peptides (293, <underline>P</underline>NLIS<underline>LLS</underline>; D47, <underline>PL</underline>LLS<underline>LLS</underline>), both of which bind to the ER&#x003b2; AF-2 surface [<xref ref-type="bibr" rid="B43">43</xref>-<xref ref-type="bibr" rid="B47">47</xref>]. Moreover, the presence of a proline residue amino-terminal to the hydrophobic groups is typical of so-called class II LXXLL motifs which are found in ER&#x003b2; interacting cofactors such as TRAP220 and RIP140[<xref ref-type="bibr" rid="B45">45</xref>]. Finally, the unusual C-terminal hydrophobic pair (ML) has been observed in ER&#x003b1; and ER&#x003b2; H12[<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B48">48</xref>], and in RIP140 NR boxes [<xref ref-type="bibr" rid="B19">19</xref>].</p><fig position="float" id="F5"><label>Figure 5</label><caption><p>Sequence comparison of putative NR box-like motif (&#x003b2;-box) with known ER AF-2 interacting peptides. Homologies between the &#x003b2;-box and ER&#x003b2; H12 or the artificial ER&#x003b2; interacting peptide 293 are indicated with thick (homologous) or thin (conserved nature of side chain) lines.</p></caption><graphic xlink:href="1478-1336-1-4-5"/></fig><p>We investigated the significance of the &#x003b2;-box in ER&#x003b2; interactions with N-CoR. As Fig. <xref ref-type="fig" rid="F6">6A</xref> shows, a synthetic &#x003b2;-box peptide competed for binding to N-CoR, albeit somewhat less efficiently than native GRIP1 NR box 2. Similar results were obtained in competition experiments that used GST-GRIP1 instead of GST-N-CoR (data not shown). The isolated &#x003b2;-box also acted as bait for a VP16-ER&#x003b2; fusion protein in mammalian cells, and did so with similar efficiency to other known ER&#x003b2; interacting peptides (Fig. <xref ref-type="fig" rid="F6">6B</xref>). Finally, mutations within the &#x003b2;-box (especially M2405A, L2406A) disrupted ER&#x003b2; interactions with N-CoR in mammalian two-hybrid assays, but did not affect TR&#x003b2; interactions (Fig. <xref ref-type="fig" rid="F6">6C</xref>). Thus, the &#x003b2;-box is sufficient to bind ER&#x003b2; and is essential for agonist-dependent ER&#x003b2; interactions with the N-CoR C-terminus.</p><fig position="float" id="F6"><label>Figure 6</label><caption><p>The N-CoR &#x003b2;-box binds ER&#x003b2;. <bold>(A) </bold>Peptide competitions. Binding of ER&#x003b2; to either bacterially expressed GST-N-CoR (amino acids 2239&#x02013;2453) was determined in the presence of increasing doses of competitor peptide (amounts shown at top refer to &#x003bc;g of peptide, plus signs refer to the presence of estradiol in the assay). <bold>(B) </bold>Interaction of ER&#x003b2; with different peptides in mammalian two-hybrid assays. A representative experiment is shown. Errors are derived from three separate wells. <bold>(C) </bold>Analysis of ER&#x003b2; interaction with mutant Gal-N-CoR fusion proteins. Values were determined as in Fig. <xref ref-type="fig" rid="F3">3</xref>.</p></caption><graphic xlink:href="1478-1336-1-4-6"/></fig><p>Next, we examined whether the &#x003b2;-box would bind other NRs. The Gal-&#x003b2;-box fusion failed to recruit the ER&#x003b1;, TR&#x003b2; or RAR&#x003b2; LBDs in mammalian two-hybrid assays (Fig. <xref ref-type="fig" rid="F7">7A</xref>). Moreover, while the &#x003b2;-box and GRIP1 NR box 2 peptides both competed for ER&#x003b2; interactions with GRIP1, only the NR box 2 peptide competed for ER&#x003b1; interactions with GRIP1 (Fig. <xref ref-type="fig" rid="F7">7B</xref>). Thus, the N-CoR &#x003b2;-box is, at least to some degree, ER&#x003b2; specific. Mutation of N-CoR to obtain a &#x003b2;-box sequence that more closely resembled a conventional LXXLL motif (T2402L) led to enhanced hormone-dependent interactions with ER&#x003b2; and permitted novel hormone-dependent interactions with ER&#x003b1; (Fig. <xref ref-type="fig" rid="F7">7C</xref>). Thus, some of the observed ER&#x003b2; specificity is probably a consequence of an unexpected ability to tolerate the absence of a leucine residue at the N-terminus of the LXXLL motif. Together, our results indicate that ER&#x003b2; has the potential to utilize its AF-2 surface to bind NR boxes within coactivators or an NR box-like sequence in the C-terminus of N-CoR.</p><fig position="float" id="F7"><label>Figure 7</label><caption><p>The &#x003b2;-box is an ER&#x003b2;-specific NR box. <bold>(A) </bold>Interactions of VP16-NR fusions with the Gal-&#x003b2;-box fusion or a GAL-GRIP1 (amino acids 610&#x02013;770) control were determined in HeLa cell transfections. A representative experiment is shown. <bold>(B) </bold>Peptide competitions for ER&#x003b1; and ER&#x003b2; binding to GST-GRIP1. Experiments utilized 10&#x003bc;g of competitor <bold>(C) </bold>Mutation of the &#x003b2;-box to resemble a consensus LXXLL motif. The panel shows the results of a mammalian two-hybrid assay in which binding of Gal-N-CoR or Gal-N-CoR T2402L to VP16-ER&#x003b2; or VP16-ER&#x003b1; was assayed.</p></caption><graphic xlink:href="1478-1336-1-4-7"/></fig></sec><sec><title>A HDAC Repressor Enhances ER&#x003b2; Activity</title><p>Since ER&#x003b2; bound N-CoR and SMRT in the presence of estrogens, we investigated the possible involvement of corepressors in the actions of agonist-bound ER&#x003b2; <italic>in vivo</italic>. To perform this experiment, we examined the effect of the HDAC inhibitor trichostatin A (TSA) on ER&#x003b2; activity in transiently transfected HeLa cells. Fig. <xref ref-type="fig" rid="F8">8A</xref> confirms that ER&#x003b1; shows stronger transcriptional activity than ER&#x003b2; at a simple ERE responsive reporter gene. TSA enhanced the basal activity of the ERE-TK reporter gene by about fifteen-fold in the absence of ER (see inset). However, TSA also equalized the relative transcriptional activity of both ERs. Fig. <xref ref-type="fig" rid="F8">8B</xref> shows that the isolated ER&#x003b1; LBD exhibited more potent transcriptional activity than the ER&#x003b2; LBD. However, both LBDs showed similar transcriptional activity in the presence of TSA. Thus, corepressor complex HDACs must play an unspecified role in restricting the transcriptional activity of both ER&#x003b2; and, in particular, the ER&#x003b2;-LBD. This is consistent with the notion that corepressors restrict the activity of agonist-bound ER&#x003b2;-LBD.</p><fig position="float" id="F8"><label>Figure 8</label><caption><p>TSA Enhances ER&#x003b2;-LBD activity. <bold>(A) </bold>Results of a HeLa cell transfection in which ER&#x003b1; and ER&#x003b2; activity was compared at a simple ERE responsive reporter gene. The value obtained in the absence of ER and ligand was set at 1 (irrespective of the presence or absence of TSA, 100 nM). Other values were calculated relative to this value. A single representative experiment is shown with errors derived from three wells. <bold>(B) </bold>Results of transfection in which ER&#x003b1; and ER&#x003b2; LBD activities were compared in the absence (left) or presence (right) of TSA (100 nM); note differences in scale. A single representative experiment is shown. Standard errors are derived from three wells.</p></caption><graphic xlink:href="1478-1336-1-4-8"/></fig></sec></sec><sec><title>Conclusions</title><p>NRs generally interact with the corepressors N-CoR and SMRT either in the absence of ligand, or in the presence of receptor antagonists, and agonists promote corepressor release [<xref ref-type="bibr" rid="B4">4</xref>]. In this study, we demonstrated that ER&#x003b2; binds to N-CoR in the presence of ER agonists such as estradiol and DES and the phytoestrogens genistein and coumestrol, but not in the presence of SERMs. Moreover, this interaction is dependent upon ER&#x003b2; AF-2, including H12, and is competed by NR box peptides but not ID peptides. The hormone-dependent component of the ER&#x003b2; /N-CoR interaction maps to the extreme C-terminus of N-CoR, which has not been previously implicated in NR interactions, and requires a sequence that resembles an ER&#x003b2;-specific NR box (PLTIRMLS, &#x003b2;-box). In this regard, ER&#x003b2; differs from ER&#x003b1;, which probably binds ID motifs in a SERM-dependent fashion [<xref ref-type="bibr" rid="B49">49</xref>,<xref ref-type="bibr" rid="B50">50</xref>] and shows reduced binding to N-CoR in the presence of estradiol [<xref ref-type="bibr" rid="B39">39</xref>]. ER&#x003b2; also differs from many other NRs, which either bind N-CoR in the absence of ligand and are released in the presence of ligand or interact with N-CoR in the presence of antagonists but not agonists [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>The fact that the mode of ER&#x003b2; interaction with N-CoR resembles that of NRs with coactivators [<xref ref-type="bibr" rid="B4">4</xref>], or with corepressors that modulate the activity of liganded NR complexes, such as RIP140 [<xref ref-type="bibr" rid="B10">10</xref>], raises the possibility that ER&#x003b2; may be able to recruit N-CoR and SMRT to estrogen-regulated promoters in response to agonists and that the balance of overall ER&#x003b2; activity in the presence of estrogens may be regulated by competition between p160s and corepressors for the same ER&#x003b2; AF-2 surface. We recognize that our studies do not directly address this issue. Our attempts to identify ER&#x003b2; mutants that differentiate between GRIP1 and N-CoR binding to analyze the role of agonist-dependent corepressor binding have not yet been successful (probably because ER&#x003b2; utilizes the same surface to bind both cofactors). Moreover, transfection of N-CoR or various mutated N-CoR derivatives did not significantly affect ER&#x003b2; activity at EREs or AP-1 sites (data not shown). We do not understand why, but in our hands, transfected N-CoR also fails to affect TR or ER&#x003b1; activity (data not shown), despite the fact that it clearly interacts with both NRs. Nevertheless, we suspect that estrogen-dependent N-CoR binding may represent an important component of the regulation of ER&#x003b2; activity. As described in the Introduction, ER&#x003b1; and ER&#x003b2; must interact differentially with factors that modulate ER activity in the presence of estrogens. The finding that estrogens suppress N-CoR binding to ER&#x003b1; [<xref ref-type="bibr" rid="B39">39</xref>], but promote N-CoR binding to ER&#x003b2; represents the first demonstration of a corepressor that shows completely distinct modes of hormone-dependent interaction with the ER isoforms. Thus, N-CoR and SMRT and their associated HDACs are excellent candidates to explain some of the differential behaviors of the ER isoforms. Consistent with this notion, the apparent weak transcriptional activity of the ER&#x003b2; LBD is a consequence of corepressor HDAC activity at some level (Fig. <xref ref-type="fig" rid="F8">8</xref>). Full verification of the importance of ER&#x003b2; interaction with N-CoR will await demonstration that ER&#x003b2; recruits N-CoR and SMRT to estrogen-regulated promoters <italic>in vivo</italic>, and that this event is related to modulation of estrogen response.</p><p>While the ER isoforms have contrasting effects on AP-1 activity in the presence of estrogens, ER&#x003b1; truncations that lack the NTD and ER&#x003b2; both enhance AP-1 activity in the presence of SERMs [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Mutational analysis of ER&#x003b1; action at AP-1 sites suggests these effects may be related to N-CoR binding [<xref ref-type="bibr" rid="B39">39</xref>], and we have proposed that SERM action at AP-1 sites may therefore involve contacts with corepressors [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B51">51</xref>]. The fact that ER&#x003b1; and ER&#x003b2; show completely different ligand preferences of interaction with N-CoR suggests that the target for SERM activation at AP-1 sites may not be N-CoR in both cases. Thus, this finding complicates our attempts to explain this unusual phenomenon. Perhaps the ER isoforms enhance AP-1 activity by superficially similar mechanisms that involve different cofactors. Alternatively, ER&#x003b1; and ER&#x003b2; action at AP-1 sites could, in fact, be mediated by SERM-dependent contacts with a common cofactor that is, as yet, unidentified. This common factor may yet prove to be N-CoR if ER&#x003b2; interactions with the &#x003b2;-box were somehow masked <italic>in vivo</italic>.</p><p>What features of the &#x003b2;-box contribute to ER&#x003b2; specificity? Intriguingly, the &#x003b2;-box contains N-terminal proline and C-terminal serine residues that extend the homology of this region to an artificial ER&#x003b2;-specific peptide [<xref ref-type="bibr" rid="B45">45</xref>]. However, the &#x003b2;-box also lacks the first Leu of the consensus LXXLL. A mutation (PL<underline>T</underline>IRML&#x0003e;PL<underline>L</underline>IRML) that restores the LXXLL consensus increases ER&#x003b2; binding to N-CoR and permits ER&#x003b1; to bind to N-CoR in the presence of estrogens in mammalian two-hybrid assays. Thus, the unusual sequence of the &#x003b2;-box contributes to ER&#x003b2; specificity and ER&#x003b2; can tolerate the absence of a conserved N-terminal leucine in LXXLL motifs. ER&#x003b2; might bind to yet more cofactors that contain variant NR boxes that resemble the &#x003b2;-box. Other aspects of ER&#x003b2; interactions with corepressors warrant further study. It will be interesting to understand whether the weaker ER&#x003b2; interactions with other regions of N-CoR (which are insensitive to ICI) play a role in ER&#x003b2; binding (Fig. <xref ref-type="fig" rid="F4">4</xref>). Finally, SMRT also binds ER&#x003b2; in the presence of estrogens, but we have not explored the structural features that promote this interaction. Intriguingly, human SMRT contains a sequence insertion at the position of the hydrophobic pair in the N-CoR &#x003b2;-box, which apparently leads to deletion of both residues (N-CoR/RMLS&#x0003e;SMRT/RLqagvmaS) [<xref ref-type="bibr" rid="B52">52</xref>]. Perhaps SMRT contains a different NR interacting motif or the N-CoR NR box sequence may be more complex than we have initially reported here.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="materials"><title>Materials</title><p>Estradiol, diethylstilbestrol (DES), tamoxifen, genistein, coumestrol, thyroid hormone, retinoic acid and trichostatin A (TSA) were purchased from Sigma (St. Louis, MO). ICI 182,780 was a gift from Alan Wakeling (Astra/Zeneca Pharmaceuticals, Macclesfield UK). Raloxifene was a gift from Stefan Nilsson (KaroBio AB, Huddinge, Sweden). Peptides were synthesized at the Biomolecular Resource Center at UCSF.</p><p>The following plasmids (pSG5-ER&#x003b1;, pSG5-ER&#x003b2; (amino acids 1&#x02013;530) [<xref ref-type="bibr" rid="B31">31</xref>], pGEX-N-CoR and pGEX-SMRT[<xref ref-type="bibr" rid="B39">39</xref>], VP16-TR&#x003b2; and Gal-N-CoR[<xref ref-type="bibr" rid="B16">16</xref>], GST-N-CoR fusions[<xref ref-type="bibr" rid="B17">17</xref>], ERE-LUC, GK1/Gal4 responsive reporter and Gal-ER&#x003b1; LBD [<xref ref-type="bibr" rid="B53">53</xref>], pM-D2, pM-D47, pM-F6[<xref ref-type="bibr" rid="B46">46</xref>]) have been previously described. VP16-ER&#x003b2; LBD and Gal-ER&#x003b2; LBD contain human ER&#x003b2; sequences and were gifts from Dr. Dale Leitmann (University of California, San Francisco). VP16-RAR-LBD was a gift from Dr. David Moore, Baylor, Houston, Texas. Gal-GRIP1 NR box (1,2,3) fusion (amino acids 610&#x02013;770) was prepared by PCR amplification of the appropriate region of GRIP1 (primers obtained from Biomolecular Resource Center, UCSF) containing EcoRI and SalI sites, the PCR fragment was digested with these enzymes and subcloned into the pM GAL4 expression vector (Clontech Laboratories, Inc. Palo Alto, CA). VP16-ER&#x003b2; mutations and Gal-N-CoR mutations were prepared using standard PCR-based site directed mutagenesis (Quickchange Kit, Stratagene, La Jolla, CA) and confirmed by sequencing. The GAL4-&#x003b2; box fusion was prepared by synthesizing oligonucleotides corresponding to the &#x003b2;-box sequence with engineered EcoRI and SalI restriction sites. Annealed and phosphorylated double stranded oligonucleotide was subcloned into the appropriate sites in the PM vector.</p></sec><sec><title>Bacterial Protein Expression and GST Pulldown Assays</title><p>GST-fusions were expressed in E. Coli BL21 [<xref ref-type="bibr" rid="B28">28</xref>]. Cultures were grown to OD600 1.5 at room temperatures (approximately 22&#x000b0;C) and protein production was initiated by addition of IPTG to 1 mM. After four hours, bacterial pellets were obtained, resuspended in 20 mM HEPES pH 7.9/ 80 mM KCl/6 mM MgCl<sub>2</sub>/1 mM Dithiothreitol/1 mM ATP/0.2 mM phenylmethylsulfonyl fluoride and protease inhibitors and sonicated. Debris was pelleted by centrifugation in an ss34 rotor for 1 hour at 12,000 rpm. The supernatant was incubated with glutathione sepharose 4B beads (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and washed as previously described. Protein preparations were stored at -20&#x000b0;C in 20% glycerol.</p><p>Labeled ERs were produced using coupled <italic>in vitro </italic>transcription-translation (TNT kit, Promega, Madison, Wisconsin). Assays were carried out in a volume of 150&#x003bc;l that contained 137.5&#x003bc;l of ice-cold protein binding buffer (PBB) along with 10&#x003bc;l of GST-bead slurry corresponding to 3&#x003bc;g of fusion protein, 1&#x003bc;l of <italic>in vitro </italic>translated protein and 1.5&#x003bc;l of ligand or vehicle and/or peptides or vehicle. PBB was freshly prepared in 24 ml aliquots composed of 20 ml A-150 (20 mM Hepes, 150 mM KCl, 10 mM MgCl2 and 1% glycerol), and 2 ml each of phosphate buffered saline supplemented, respectively, with 1% Triton X-100 and 1% NP-40. PMSF, DTT, BSA and protease inhibitor cocktail (Novagen) were added to 0.1 mM, 1 mM, 2&#x003bc;g/ml and 1/1000 dilution respectively. The mix was incubated for two hours in the cold room with gentle agitation, the beads were pelleted by spinning briefly on a bench top Eppendorf centrifuge, washed four times with PBB containing no BSA, and the pellet was dried under vacuum for twenty minutes. Labeled protein was subjected to SDS-polyacrylamide gel electrophoresis and autoradiography.</p></sec><sec><title>Transfections</title><p>HeLa cells were grown in DME/F-12 Ham's 1:1 mix, without phenol red (Sigma) containing 10% iron supplemented calf serum (Sigma) and pen-strep. Cells were transfected by electroporation [<xref ref-type="bibr" rid="B28">28</xref>]. Transfections contained 2&#x003bc;g of luciferase and actin-&#x003b2;-galactosidase reporters and, where indicated, 1&#x003bc;g of ER, VP16-fusion protein or GAL4-fusion protein expression vectors or empty vector controls. Luciferase and &#x003b2;-galactosidase activities were measured using luciferase (Promega, Madison, WI) and Galacto-Light assay systems (Tropix, Bedford, MA).</p></sec></sec><sec><title>List of Abbreviations</title><p>AIB1 Amplified in breast cancer 1.</p><p>AF-1 Activation function 1</p><p>AF-2 Activation function 2</p><p>AP-1 Activator protein 1</p><p>CARM1 Coactivator associated arginine methyl-transferase 1.</p><p>CBP CREB binding protein.</p><p>CRE Cyclic Amp response element</p><p>DAX Dosage sensitive sex reversal adrenal hyperplasia congenital critical region on the X-chromosome, region 1.</p><p>DES Diethylstilbestrol</p><p>DNA Deoxyribonucleic acid</p><p>DBD DNA binding domain</p><p>TNF&#x003b1; Tumor necrosis factor alpha 1</p><p>E2 Estradiol</p><p>ER&#x003b1; Estrogen receptor alpha</p><p>ER&#x003b2; Estrogen receptor beta</p><p>ERE, Estrogen response element</p><p>GRIP1 Glucocorticoid receptor interacting protein 1;</p><p>GST Glutathione S-transferase</p><p>H Helix</p><p>HAT Histone acetyl-transferase</p><p>HET-SAFB Hsp27-ERE-TATA binding protein/scaffold attachment factor B.</p><p>HDAC Histone de-acetylase</p><p>ID Interaction domain.</p><p>LBD Ligand binding domain</p><p>NR Nuclear receptor</p><p>NTD Amino terminal domain</p><p>N-CoR Nuclear receptor corepressor</p><p>PBS Phosphate buffered saline</p><p>PCR Polymerase chain reaction</p><p>PERC PGC-1 related estrogen receptor coactivator</p><p>PGC-1 Peroxisome proliferator activated receptor gamma coactivator 1.</p><p>RAR Retinoic acid receptor</p><p>REA Repressor of estrogen receptor activity</p><p>RIP140 Receptor interacting protein of 140 Kd</p><p>SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis</p><p>SMRT Silencing Mediator of Retinoid and Thyroid Responsive transcription.</p><p>SERM Selective estrogen receptor modulator(s)</p><p>SHP Short heterodimer partner</p><p>SRC-1 Steroid receptor coactivator 1</p><p>TR Thyroid receptor</p><p>TRAP220 TR associated protein of 200 Kd.</p></sec><sec><title>Competing Interests</title><p><bold>PW </bold>None declared.</p><p><bold>CV </bold>None declared</p><p><bold>PN </bold>None declared</p><p><bold>RHP Jr. </bold>None declared.</p><p><bold>AM </bold>Since the studies were performed, has moved to Plexxikon, a company with interests in protein structure.</p><p><bold>BLW </bold>Since the studies were performed, has moved to Plexxikon, a company with interests in protein structure.</p><p><bold>JDB </bold>has proprietary interests in, and serves as consultant and deputy director to Karo Bio AB, a Swedish company that develops pharmaceuticals that target NRs.</p><p><bold>PJK </bold>has significant financial interests in, and is a consultant and former director of, Karo Bio AB.</p></sec><sec><title>Authors Contributions</title><p>PW Conceived and directed the studies, wrote the paper, performed plasmid constructions and transfection studies.</p><p>CV Performed transfection, mutagenesis and GST pulldown experiments under guidance of PW.</p><p>PN Performed transfection, mutagenesis and GST pulldown experiments under guidance of PW.</p><p>RHP Jr. Provided intellectual input in the study design.</p><p>AM. Expressed GST N-CoR fragments for pulldown studies with ER&#x003b2;.</p><p>BW Designed bacterial expression vectors for N-CoR fragments, cloned cDNA fragments for GST-N-CoR expression vectors and provided intellectual input into the study design.</p><p>JDB. Directed studies of NR interactions with N-CoR and provided intellectual input into study design.</p><p>PJK. Co-directed studies along with PW and provided intellectual input into study design.</p><p>All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by NIH grants to PJK (DK51083 and CA80210) and JDB (DK51281).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>RCJ</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name></person-group><article-title>The nuclear hormone receptor gene superfamily</article-title><source>Annu Rev Med</source><year>1995</year><volume>46</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">7598477</pub-id><pub-id pub-id-type="doi">10.1146/annurev.med.46.1.443</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weatherman</surname><given-names>RV</given-names></name><name><surname>Fletterick</surname><given-names>RJ</given-names></name><name><surname>Scanlan</surname><given-names>TS</given-names></name></person-group><article-title>Nuclear-receptor ligands and ligand-binding domains</article-title><source>Annu Rev Biochem</source><year>1999</year><volume>68</volume><fpage>559</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">10872460</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.68.1.559</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>O'Malley</surname><given-names>BW</given-names></name></person-group><article-title>Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt</article-title><source>Ann N Y Acad Sci</source><year>2001</year><volume>949</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11795367</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name></person-group><article-title>The coregulator exchange in transcriptional functions of nuclear receptors</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>121</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">10652267</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Rose</surname><given-names>DW</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name></person-group><article-title>Nuclear receptor coactivators</article-title><source>Curr Opin Cell Biol</source><year>1997</year><volume>9</volume><fpage>222</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">9069256</pub-id><pub-id pub-id-type="doi">10.1016/S0955-0674(97)80066-X</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Koh</surname><given-names>SS</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Schurter</surname><given-names>BT</given-names></name><name><surname>Aswad</surname><given-names>DW</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Regulation of transcription by a protein methyltransferase</article-title><source>Science</source><year>1999</year><volume>284</volume><fpage>2174</fpage><lpage>2177</lpage><pub-id pub-id-type="pmid">10381882</pub-id><pub-id pub-id-type="doi">10.1126/science.284.5423.2174</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>CX</given-names></name><name><surname>Okano</surname><given-names>HJ</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name></person-group><article-title>Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action</article-title><source>Mol Cell</source><year>2000</year><volume>5</volume><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">10882104</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Park</surname><given-names>CW</given-names></name><name><surname>Graves</surname><given-names>R</given-names></name><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis</article-title><source>Cell</source><year>1998</year><volume>92</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">9529258</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81410-5</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knutti</surname><given-names>D</given-names></name><name><surname>Kralli</surname><given-names>A</given-names></name></person-group><article-title>PGC-1, a versatile coactivator</article-title><source>Trends Endocrinol Metab</source><year>2001</year><volume>12</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11551810</pub-id><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00457-X</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavailles</surname><given-names>V</given-names></name><name><surname>Dauvois</surname><given-names>S</given-names></name><name><surname>L'Horset</surname><given-names>F</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name><name><surname>Hoare</surname><given-names>S</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name></person-group><article-title>Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor</article-title><source>Embo J</source><year>1995</year><volume>14</volume><fpage>3741</fpage><lpage>3751</lpage><pub-id pub-id-type="pmid">7641693</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moraitis</surname><given-names>AN</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>CC</given-names></name></person-group><article-title>Novel mechanism of nuclear receptor corepressor interaction dictated by activation function 2 helix determinants</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>6831</fpage><lpage>6841</lpage><pub-id pub-id-type="pmid">12215540</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.19.6831-6841.2002</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seol</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><article-title>An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors</article-title><source>Science</source><year>1996</year><volume>272</volume><fpage>1336</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">8650544</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Thomsen</surname><given-names>JS</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Treuter</surname><given-names>E</given-names></name></person-group><article-title>DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>39855</fpage><lpage>39859</lpage><pub-id pub-id-type="pmid">11053406</pub-id><pub-id pub-id-type="doi">10.1074/jbc.C000567200</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montano</surname><given-names>MM</given-names></name><name><surname>Ekena</surname><given-names>K</given-names></name><name><surname>Delage-Mourroux</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Martini</surname><given-names>P</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name></person-group><article-title>An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>6947</fpage><lpage>6952</lpage><pub-id pub-id-type="pmid">10359819</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.12.6947</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oesterreich</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Hopp</surname><given-names>T</given-names></name><name><surname>Fuqua</surname><given-names>SA</given-names></name><name><surname>Michaelis</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>HH</given-names></name><name><surname>Davie</surname><given-names>JR</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>AV</given-names></name></person-group><article-title>Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation</article-title><source>Mol Endocrinol</source><year>2000</year><volume>14</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">10707955</pub-id><pub-id pub-id-type="doi">10.1210/me.14.3.369</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>CM</given-names></name><name><surname>Valentine</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs)</article-title><source>Mol Endocrinol</source><year>2000</year><volume>14</volume><fpage>1976</fpage><lpage>1985</lpage><pub-id pub-id-type="pmid">11117528</pub-id><pub-id pub-id-type="doi">10.1210/me.14.12.1976</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Tagami</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name><name><surname>Fletterick</surname><given-names>RJ</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name><name><surname>West</surname><given-names>BL</given-names></name></person-group><article-title>TR surfaces and conformations required to bind nuclear receptor corepressor</article-title><source>Mol Endocrinol</source><year>2002</year><volume>16</volume><fpage>271</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">11818500</pub-id><pub-id pub-id-type="doi">10.1210/me.16.2.271</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Ribeiro</surname><given-names>RC</given-names></name><name><surname>Wagner</surname><given-names>RL</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Apriletti</surname><given-names>JW</given-names></name><name><surname>Fletterick</surname><given-names>RJ</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>West</surname><given-names>BL</given-names></name></person-group><article-title>Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors</article-title><source>Science</source><year>1998</year><volume>280</volume><fpage>1747</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">9624051</pub-id><pub-id pub-id-type="doi">10.1126/science.280.5370.1747</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heery</surname><given-names>DM</given-names></name><name><surname>Kalkhoven</surname><given-names>E</given-names></name><name><surname>Hoare</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name></person-group><article-title>A signature motif in transcriptional co-activators mediates binding to nuclear receptors</article-title><source>Nature</source><year>1997</year><volume>387</volume><fpage>733</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">9192902</pub-id><pub-id pub-id-type="doi">10.1038/42750</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>MG</given-names></name></person-group><article-title>Transcriptional activation by oestrogen receptors</article-title><source>Biochem Soc Symp</source><year>1998</year><volume>63</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9513710</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><name><surname>Montano</surname><given-names>MM</given-names></name><name><surname>Ediger</surname><given-names>TR</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ekena</surname><given-names>K</given-names></name><name><surname>Lazennec</surname><given-names>G</given-names></name><name><surname>Martini</surname><given-names>PG</given-names></name><name><surname>McInerney</surname><given-names>EM</given-names></name><name><surname>Delage-Mourroux</surname><given-names>R</given-names></name><name><surname>Weis</surname><given-names>K</given-names></name><name><surname>Katzenellenbogen</surname><given-names>JA</given-names></name></person-group><article-title>Estrogen receptors: selective ligands, partners, and distinctive pharmacology</article-title><source>Recent Prog Horm Res</source><year>2000</year><volume>55</volume><fpage>163</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">11036937</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couse</surname><given-names>JE</given-names></name><name><surname>Mahato</surname><given-names>D</given-names></name><name><surname>Eddy</surname><given-names>EM</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name></person-group><article-title>Molecular mechanism of estrogen action in the male: insights from the estrogen receptor null mice</article-title><source>Reprod Fertil Dev</source><year>2001</year><volume>13</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">11800160</pub-id><pub-id pub-id-type="doi">10.1071/RD00128</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Role of estrogen receptor beta in estrogen action</article-title><source>Annu Rev Physiol</source><year>2001</year><volume>63</volume><fpage>165</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">11181953</pub-id><pub-id pub-id-type="doi">10.1146/annurev.physiol.63.1.165</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Lemmen</surname><given-names>JG</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Corton</surname><given-names>JC</given-names></name><name><surname>Safe</surname><given-names>SH</given-names></name><name><surname>van der Saag</surname><given-names>PT</given-names></name><name><surname>van der Burg</surname><given-names>B</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta</article-title><source>Endocrinology</source><year>1998</year><volume>139</volume><fpage>4252</fpage><lpage>4263</lpage><pub-id pub-id-type="pmid">9751507</pub-id><pub-id pub-id-type="doi">10.1210/en.139.10.4252</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JM</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>5566</fpage><lpage>5578</lpage><pub-id pub-id-type="pmid">10579320</pub-id><pub-id pub-id-type="doi">10.1210/en.140.12.5566</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>K</given-names></name><name><surname>Delaunay</surname><given-names>F</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Estrogen receptor beta acts as a dominant regulator of estrogen signaling</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>4970</fpage><lpage>4978</lpage><pub-id pub-id-type="pmid">11042684</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203828</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>J</given-names></name><name><surname>Ribeiro</surname><given-names>RC</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name><name><surname>Leitman</surname><given-names>DC</given-names></name></person-group><article-title>Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>15161</fpage><lpage>15166</lpage><pub-id pub-id-type="pmid">10611355</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.26.15161</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Lopez</surname><given-names>GN</given-names></name><name><surname>Uht</surname><given-names>RM</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens</article-title><source>Mol Endocrinol</source><year>1995</year><volume>9</volume><fpage>443</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">7659088</pub-id><pub-id pub-id-type="doi">10.1210/me.9.4.443</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MM</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>CM</given-names></name><name><surname>Hilty</surname><given-names>K</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Uht</surname><given-names>RM</given-names></name><name><surname>Price</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>24353</fpage><lpage>24360</lpage><pub-id pub-id-type="pmid">11986316</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M201829200</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paech</surname><given-names>K</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Gustafsson</surname><given-names>J</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Scanlan</surname><given-names>TS</given-names></name></person-group><article-title>Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>1508</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">9278514</pub-id><pub-id pub-id-type="doi">10.1126/science.277.5331.1508</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Valentine</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>GN</given-names></name><name><surname>Kwok</surname><given-names>GR</given-names></name><name><surname>McInerney</surname><given-names>E</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions</article-title><source>Mol Endocrinol</source><year>1999</year><volume>13</volume><fpage>1672</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">10517669</pub-id><pub-id pub-id-type="doi">10.1210/me.13.10.1672</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weatherman</surname><given-names>RV</given-names></name><name><surname>Scanlan</surname><given-names>TS</given-names></name></person-group><article-title>Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>3827</fpage><lpage>3832</lpage><pub-id pub-id-type="pmid">11060287</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M005414200</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>GB</given-names></name><name><surname>Tremblay</surname><given-names>A</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex</article-title><source>Mol Cell Biol</source><year>1999</year><volume>19</volume><fpage>1919</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">10022879</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>DP</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Norris</surname><given-names>JD</given-names></name></person-group><article-title>Development of peptide antagonists that target estrogen receptor-cofactor interactions</article-title><source>J Steroid Biochem Mol Biol</source><year>2000</year><volume>74</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">11162941</pub-id><pub-id pub-id-type="doi">10.1016/S0960-0760(00)00109-6</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Estrogen receptor-cofactor interactions as targets for novel drug discovery</article-title><source>Ernst Schering Res Found Workshop</source><year>2001</year><fpage>181</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">11394045</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>GB</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>Coregulators of estrogen receptor action</article-title><source>Crit Rev Eukaryot Gene Expr</source><year>2002</year><volume>12</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12433063</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seol</surname><given-names>W</given-names></name><name><surname>Hanstein</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><article-title>Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner)</article-title><source>Mol Endocrinol</source><year>1998</year><volume>12</volume><fpage>1551</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">9773978</pub-id><pub-id pub-id-type="doi">10.1210/me.12.10.1551</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kressler</surname><given-names>D</given-names></name><name><surname>Schreiber</surname><given-names>SN</given-names></name><name><surname>Knutti</surname><given-names>D</given-names></name><name><surname>Kralli</surname><given-names>A</given-names></name></person-group><article-title>The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>13918</fpage><lpage>13925</lpage><pub-id pub-id-type="pmid">11854298</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M201134200</pub-id></citation></ref><ref id="B39"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>Differential SERM effects on corepressor binding dictate ER alpha activity in vivo</article-title><source>J Biol Chem</source><year>2002</year></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>XF</given-names></name><name><surname>Anderson</surname><given-names>CM</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Uht</surname><given-names>RM</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities</article-title><source>Mol Endocrinol</source><year>1998</year><volume>12</volume><fpage>302</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">9482670</pub-id><pub-id pub-id-type="doi">10.1210/me.12.2.302</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darimont</surname><given-names>BD</given-names></name><name><surname>Wagner</surname><given-names>RL</given-names></name><name><surname>Apriletti</surname><given-names>JW</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Baxter</surname><given-names>JD</given-names></name><name><surname>Fletterick</surname><given-names>RJ</given-names></name><name><surname>Yamamoto</surname><given-names>KR</given-names></name></person-group><article-title>Structure and specificity of nuclear receptor-coactivator interactions</article-title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>3343</fpage><lpage>3356</lpage><pub-id pub-id-type="pmid">9808622</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>A novel role for helix 12 of retinoid X receptor in regulating repression</article-title><source>Mol Cell Biol</source><year>1999</year><volume>19</volume><fpage>6448</fpage><lpage>6457</lpage><pub-id pub-id-type="pmid">10454590</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brzozowski</surname><given-names>AM</given-names></name><name><surname>Pike</surname><given-names>AC</given-names></name><name><surname>Dauter</surname><given-names>Z</given-names></name><name><surname>Hubbard</surname><given-names>RE</given-names></name><name><surname>Bonn</surname><given-names>T</given-names></name><name><surname>Engstrom</surname><given-names>O</given-names></name><name><surname>Ohman</surname><given-names>L</given-names></name><name><surname>Greene</surname><given-names>GL</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Carlquist</surname><given-names>M</given-names></name></person-group><article-title>Molecular basis of agonism and antagonism in the oestrogen receptor</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">9338790</pub-id><pub-id pub-id-type="doi">10.1038/39645</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shiau</surname><given-names>AK</given-names></name><name><surname>Barstad</surname><given-names>D</given-names></name><name><surname>Loria</surname><given-names>PM</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name><name><surname>Greene</surname><given-names>GL</given-names></name></person-group><article-title>The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</article-title><source>Cell</source><year>1998</year><volume>95</volume><fpage>927</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">9875847</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81717-1</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Gron</surname><given-names>H</given-names></name><name><surname>Paige</surname><given-names>LA</given-names></name><name><surname>Hamilton</surname><given-names>PT</given-names></name><name><surname>Kenan</surname><given-names>DJ</given-names></name><name><surname>Fowlkes</surname><given-names>D</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta</article-title><source>Mol Cell Biol</source><year>1999</year><volume>19</volume><fpage>8226</fpage><lpage>8239</lpage><pub-id pub-id-type="pmid">10567548</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Paige</surname><given-names>LA</given-names></name><name><surname>Christensen</surname><given-names>DJ</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Huacani</surname><given-names>MR</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Hamilton</surname><given-names>PT</given-names></name><name><surname>Fowlkes</surname><given-names>DM</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Peptide antagonists of the human estrogen receptor</article-title><source>Science</source><year>1999</year><volume>285</volume><fpage>744</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">10426998</pub-id><pub-id pub-id-type="doi">10.1126/science.285.5428.744</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paige</surname><given-names>LA</given-names></name><name><surname>Christensen</surname><given-names>DJ</given-names></name><name><surname>Gron</surname><given-names>H</given-names></name><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Gottlin</surname><given-names>EB</given-names></name><name><surname>Padilla</surname><given-names>KM</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Ballas</surname><given-names>LM</given-names></name><name><surname>Hamilton</surname><given-names>PT</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name><name><surname>Fowlkes</surname><given-names>DM</given-names></name></person-group><article-title>Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>3999</fpage><lpage>4004</lpage><pub-id pub-id-type="pmid">10097152</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.7.3999</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>AC</given-names></name><name><surname>Brzozowski</surname><given-names>AM</given-names></name><name><surname>Hubbard</surname><given-names>RE</given-names></name><name><surname>Bonn</surname><given-names>T</given-names></name><name><surname>Thorsell</surname><given-names>AG</given-names></name><name><surname>Engstrom</surname><given-names>O</given-names></name><name><surname>Ljunggren</surname><given-names>J</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Carlquist</surname><given-names>M</given-names></name></person-group><article-title>Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist</article-title><source>Embo J</source><year>1999</year><volume>18</volume><fpage>4608</fpage><lpage>4618</lpage><pub-id pub-id-type="pmid">10469641</pub-id><pub-id pub-id-type="doi">10.1093/emboj/18.17.4608</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>DiRenzo</surname><given-names>J</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>843</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">11136970</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Sherk</surname><given-names>A</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>A negative coregulator for the human ER</article-title><source>Mol Endocrinol</source><year>2002</year><volume>16</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">11875103</pub-id><pub-id pub-id-type="doi">10.1210/me.16.3.459</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Agard</surname><given-names>DA</given-names></name><name><surname>Greene</surname><given-names>GL</given-names></name><name><surname>Scanlan</surname><given-names>TS</given-names></name><name><surname>Shiau</surname><given-names>AK</given-names></name><name><surname>Uht</surname><given-names>RM</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name></person-group><article-title>Estrogen receptor pathways to AP-1</article-title><source>J Steroid Biochem Mol Biol</source><year>2000</year><volume>74</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">11162939</pub-id><pub-id pub-id-type="doi">10.1016/S0960-0760(00)00108-4</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ordentlich</surname><given-names>P</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Genin</surname><given-names>A</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>Unique forms of human and mouse nuclear receptor corepressor SMRT</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>2639</fpage><lpage>2644</lpage><pub-id pub-id-type="pmid">10077563</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.6.2639</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Shinsako</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>MP</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>McKinerney</surname><given-names>E</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name><name><surname>Kushner</surname><given-names>PJ</given-names></name></person-group><article-title>Estrogen receptor activation function 1 works by binding p160 coactivator proteins</article-title><source>Mol Endocrinol</source><year>1998</year><volume>12</volume><fpage>1605</fpage><lpage>1618</lpage><pub-id pub-id-type="pmid">9773983</pub-id><pub-id pub-id-type="doi">10.1210/me.12.10.1605</pub-id></citation></ref></ref-list></back></article> 